2017
Evidence that polygenic risk for psychotic disorder is expressed in the domain of neurodevelopment, emotion regulation and attribution of salience
van Os J, van der Steen Y, Islam M, Gülöksüz S, Rutten B, Simons C. Evidence that polygenic risk for psychotic disorder is expressed in the domain of neurodevelopment, emotion regulation and attribution of salience. Psychological Medicine 2017, 47: 2421-2437. PMID: 28436345, DOI: 10.1017/s0033291717000915.Peer-Reviewed Original ResearchConceptsPolygenic risk scoresHealthy comparison subjectsPsychotic disordersAttribution of salienceAffective episodesComparison subjectsIntelligence quotientTotal scorePolygenic riskFirst-degree relativesElevated genetic riskLower intelligence quotientManic episodesHealthy relativesRisk scoreNeurodevelopmental alterationsDepression subscaleLifetime ratesSimilar associationPsychosis riskFloor effectsGenetic riskPositive subscalePsychosis phenotypeDisorders
2013
Clinical potential of cariprazine in the treatment of acute mania.
Altınbaş K, Guloksuz S, Oral E. Clinical potential of cariprazine in the treatment of acute mania. Psychiatria Danubina 2013, 25: 207-13. PMID: 24048386.Peer-Reviewed Original ResearchConceptsAcute manic episodeAdverse eventsManic episodesTreatment-emergent adverse eventsD3 receptor activityFlexible-dose studyCommon adverse eventsSerious adverse eventsCommon side effectsAdditional therapeutic benefitSecond-generation antipsychoticsCariprazine treatmentDopamine agonismPlacebo armAcute maniaExtrapyramidal symptomsQTc prolongationGeneration antipsychoticsHistamine H1Novel antipsychoticsProlactin increaseMetabolic disturbancesClinical trialsClinical dataDopamine D2